Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children (CONCOR-KIDS)
Hospitalized Children, Covid-19 Infection
About this trial
This is an interventional treatment trial for Hospitalized Children focused on measuring covid-19, hospitalized children, convalescent plasma therapy
Eligibility Criteria
Inclusion Criteria:
- Age 0 to <19 years old
- Hospitalized with symptoms compatible with COVID-19 illness
- Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen prior to randomization.
- ABO compatible convalescent plasma available
Exclusion Criteria:
- Onset of symptoms began >12 days before screening
- History of adverse reactions to blood products or other contraindication to transfusion
- Refusal of plasma for religious or other reasons
- Acute heart failure with fluid overload
- Any condition or diagnosis, that could in the opinion of the Site Principal Investigator interfere with the participant's ability to comply with study instructions, or put the participant at risk
- Anticipated discharge within 24 hours
Note: The intent of this exclusion criteria is to only include participants with acute COVID-19 infections. This protocol is not intended to include participants with post-infectious complications. In cases where the distinction is not clear, participant eligibility will be discussed with the study steering committee prior to enrollment.
Sites / Locations
- Alberta Children's Hospital
- Stollery Children's Hospital
- BC Children's Hospital
- Winnipeg Children's Hospital
- IWK Health Centre
- McMaster Children's Hospital
- Kingston Health Sciences Centre
- Children's Hospital
- Children's Hospital of Eastern Ontario
- The Hospital for Sick Children
- CHU Sainte-Justine
- McGill Univ Health Ctr - Montreal Children's Hospital
- Jim Pattison Children's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Convalescent Plasma + Standard of Care (C19-CP + SoC)
Standard of Care (SoC)
Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
Participants will receive standard of care while being hospitalized for COVID-19.